Eliem Therapeutics Inc ELYM:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 08/12/22 EDT
2.94UNCH (UNCH)
Volume
17,019
52 week range
2.52 - 29.69
Loading...
  • Open2.86
  • Day High3.01
  • Day Low2.86
  • Prev Close2.94
  • 52 Week High29.69
  • 52 Week High Date08/30/21
  • 52 Week Low2.52
  • 52 Week Low Date05/25/22

Key Stats

  • Market Cap78.12M
  • Shares Out26.57M
  • 10 Day Average Volume0.04M
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-71.89

KEY STATS

  • Open2.86
  • Day High3.01
  • Day Low2.86
  • Prev Close2.94
  • 52 Week High29.69
  • 52 Week High Date08/30/21
  • 52 Week Low2.52
  • 52 Week Low Date05/25/22
  • Market Cap78.12M
  • Shares Out26.57M
  • 10 Day Average Volume0.04M
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-71.89

RATIOS/PROFITABILITY

  • EPS (TTM)-1.89
  • P/E (TTM)-1.55
  • Fwd P/E (NTM)-2.00
  • EBITDA (TTM)-41.925M
  • ROE (TTM)-81.36%
  • Revenue (TTM)0.00
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)0.00%

EVENTS

  • Earnings Date09/13/2022(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Eliem Therapeutics Inc

There is no recent news for this security.

Content From Our Affiliates

Profile

MORE
Eliem Therapeutics, Inc. is a clinical-stage biotechnology company. The Company focuses on developing novel therapies for neuronal excitability disorders that addresses unmet needs in chronic pain, neuropsychiatry, epilepsy, and other disorders of the perishable and central nervous system. The Company offers two lead clinical-stage candidates: ETX-810 and ETX-155. ETX-810 is a palmitoylethanolamide (PEA) prodrug developed for the treatment of diabetic peripheral neuropathic...
Andrew Levin M.D., Ph.D.
Independent Chairman of the Board
Robert Azelby
President, Chief Executive Officer, Director
Erin Lavelle
Chief Financial Officer, Chief Operating Officer, Executive Vice President
Valerie Morisset Ph.D.
Executive Vice President - Research and Development, Chief Scientific Officer
James Bucher J.D.
Executive Vice President, General Counsel
Address
23515 NE NOVELTY HILL ROAD
SUITE B221 #125
Redmond, WA
98053
United States

Top Peers

SYMBOLLASTCHG%CHG
FREQ
Frequency Therapeutics Inc
2.01+0.05+2.55%
AMTI
Applied Molecular Transport Inc.
1.96UNCHUNCH
MBIO
Mustang Bio Inc
0.7501+0.012+1.63%
BLRX
BioLine RX Ltd
1.87+0.11+6.25%
ETNB
89Bio Inc
4.35+0.27+6.62%